Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032

The Hereditary Angioedema Therapeutics Market is projected to reach USD 5.28 Billion in 2026. It is expected to continue growing at a CAGR of 5.53%, reaching USD 7.31 Billion by 2032.

Hereditary angioedema therapeutics are moving from episodic emergency intervention toward personalized, prevention-led disease control across on-demand treatment, short-term prophylaxis, and long-term prophylaxis. HAE is a rare, autosomal dominant, bradykinin-mediated disorder most often linked to quantitative or functional C1 esterase inhibitor deficiency, causing recurrent swelling of the skin, gastrointestinal tract, and airway; laryngeal involvement remains a critical safety concern. Current treatment strategies focus on rapid attack resolution, reduction of attack frequency, patient self-administration, and quality-of-life improvement through C1-INH replacement, bradykinin B2 receptor antagonism, plasma kallikrein inhibition, factor XIIa inhibition, and RNA-targeted approaches.

Transformative Shifts in the Hereditary Angioedema Treatment Landscape

The hereditary angioedema therapeutics landscape is being reshaped by three interlocking shifts: earlier self-administration, broader prophylaxis choices, and new molecular targets within the kallikrein-kinin pathway. International guidance recommends that all patients have on-demand therapy and that long-term prophylaxis be individualized based on disease activity, quality of life, treatment burden, patient preference, and health-resource availability; first-line prophylaxis has historically included plasma-derived C1-INH, lanadelumab, and berotralstat. Since 2025, regulatory decisions have added important modalities, including an oral plasma kallikrein inhibitor for acute attacks, a factor XIIa inhibitor for prevention, and a prekallikrein-directed antisense oligonucleotide for prevention, expanding clinical decision-making from route-of-administration convenience to mechanism-based sequencing and breakthrough-attack management.

Cumulative Impact of Artificial Intelligence on HAE Therapeutics

Artificial intelligence is beginning to affect hereditary angioedema therapeutics less as a stand-alone therapy and more as an enabling layer across diagnosis, trial design, real-world evidence, and patient support. HAE is frequently confused with allergy, gastrointestinal disease, or nonspecific swelling, and studies using electronic medical records show that structured and unstructured clinical data can be leveraged to proactively identify rare-disease patients who may otherwise remain undiagnosed. In Japan-focused algorithm development, researchers highlighted the difficulty of machine learning in HAE because positive training datasets are small, yet the work demonstrates how symptom patterns such as recurrent abdominal pain and edema can support earlier suspicion. Quantitative systems pharmacology models of the kallikrein-kinin pathway also create a data-driven foundation for simulating bradykinin dynamics, treatment adherence, pharmacokinetics, and prophylaxis selection, while responsible AI governance remains essential for bias control, explainability, privacy, and validation across ethnic and health-system contexts.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

In Asia-Pacific, hereditary angioedema therapeutics are advancing through Japan and Australia’s more established regulatory pathways while China, India, South Korea, and several Southeast Asian systems continue to prioritize diagnostic capacity, specialist awareness, and equitable access. Asia-Pacific studies report that many countries still lack consistent access to diagnostic testing and evidence-based therapies, with resource-constrained guidance from the Indian subcontinent emphasizing that intravenous plasma-derived C1-INH may be the only available first-line option in some settings. North America remains a high-evidence, guideline-driven environment, with U.S. regulatory approvals in 2025 for new prophylactic and on-demand mechanisms and Canadian guidance emphasizing comprehensive care, individualized prophylaxis, and immediate access to attack therapy. Latin America is characterized by active clinical expertise in Brazil and Mexico but persistent access and diagnosis gaps; Brazilian guidance supports crisis treatment with icatibant or plasma-derived C1 inhibitor, while Mexico-focused real-world literature documents long diagnostic delays and uneven access to specialized care. Europe benefits from centralized EU authorization, national reference networks, and recent approvals for factor XIIa inhibition, oral on-demand plasma kallikrein inhibition, and RNA-targeted prophylaxis, while country-level reimbursement remains the key determinant of treatment availability. The Middle East has developed regional Delphi consensus recommendations because implementation of global HAE guidance requires adaptation to heterogeneous awareness, diagnostic access, and self-administration infrastructure. Africa remains the most access-constrained region in the evidence base, with South African data showing that limited on-demand therapy availability and cost concerns are linked to worse disease control and quality-of-life outcomes, making emergency-treatment readiness and specialist referral pathways central priorities.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7 & NATO

Across ASEAN, hereditary angioedema therapeutics are shaped by uneven diagnostic infrastructure, variable access to C4, C1-INH level, C1-INH functional testing, and limited specialist density, making regional education, referral algorithms, and affordable on-demand treatment availability more important than broad formulary breadth. In the GCC, the Middle East Delphi consensus points to the value of harmonized specialist education, patient self-administration training, and regional adaptation of global guidance across Gulf health systems. The European Union provides a strong regulatory convergence model through centralized medicines assessment and orphan-medicine pathways, enabling multi-country authorization for recent HAE therapies while leaving reimbursement and patient access to national decision-making. BRICS countries combine advanced clinical centers with significant access heterogeneity: Brazil has national guidance, Russia has emerging regional experience with modern prophylaxis, India has resource-constrained consensus guidance, China has updated expert consensus and expanding awareness initiatives, and South Africa illustrates the quality-of-life impact of restricted on-demand access. The G7 group concentrates several of the most mature HAE care environments, including the United States, Canada, the United Kingdom, Germany, France, Italy, and Japan, where regulatory approvals, clinical trial participation, and specialist centers support evidence generation and therapy uptake. NATO should be viewed as a continuity-of-care and emergency-readiness lens rather than a medicines payer; because many NATO members overlap with G7 and EU systems, manufacturers and care networks should prioritize cross-border documentation, travel-ready rescue plans, and alignment with nationally approved on-demand options for mobile populations.

Key Country Insights Across Major HAE Therapeutics Markets

In the United States, 2025 marked a major therapeutic expansion as regulators cleared new HAE options spanning factor XIIa inhibition, oral on-demand kallikrein inhibition, and RNA-targeted prophylaxis for patients aged 12 years and older where indicated. Canada is reinforcing guideline-based management through updated international and Canadian recommendations and authorization of factor XIIa inhibition for routine prevention in patients 12 years and older. Mexico shows a high unmet-need profile, with real-world research describing long diagnostic delays and pediatric literature calling out underdiagnosis and inequitable access to specialized therapies. Brazil has one of Latin America’s strongest documented HAE guidance bases, with recommendations supporting C1-INH and bradykinin B2 receptor antagonist use for acute crises while access pathways continue to shape real-world treatment. In the United Kingdom, recent approvals for oral on-demand treatment and RNA-targeted prophylaxis, alongside commissioned treatment algorithms, support a more structured rare-immunology pathway. Germany, France, Italy, and Spain operate within the EU authorization framework and benefit from specialist reference centers, but Spain-specific patient-journey research still identifies training, early diagnosis, and high-cost therapy access as continuing issues. Russia’s recent regional experience with modern prophylaxis indicates growing clinical adoption in specialist settings, although availability remains location-dependent. China’s updated expert consensus and Greater Bay Area access initiatives show a shift from awareness-building toward structured diagnosis and treatment alignment. India’s consensus for resource-constrained settings emphasizes pragmatic diagnosis and C1-INH-based management where modern options are limited. Japan has progressively broadened approved HAE options, with official review documents listing icatibant, intravenous C1-inactivator therapy, berotralstat, lanadelumab, and garadacimab among approved medicines. Australia has accelerated access with 2025 approval of garadacimab for routine prevention and approval of sebetralstat for attacks in patients aged 12 years and older. South Korea sits within the wider Asia-Pacific access pattern, where specialist awareness is improving but country-specific reimbursement and diagnostic standardization remain decisive for patient-level uptake.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize diagnosis-to-treatment integration rather than isolated product positioning. The most actionable pathway is to support specialist referral triggers in allergy, emergency medicine, gastroenterology, pediatrics, dermatology, and primary care; ensure every diagnosed patient has a written action plan and access to effective on-demand treatment; and design education around the difference between bradykinin-mediated HAE and histamine-mediated angioedema. Portfolio strategy should address both acute and preventive needs because breakthrough attacks can persist even in patients receiving long-term prophylaxis, and treatment burden remains tied to route of administration, portability, training, and payer authorization. Leaders should also build real-world evidence programs that track attack frequency, time to treatment, rescue-medication use, patient-reported outcomes, quality of life, adherence, and reasons for delayed treatment, while tailoring access programs for regions where C1-INH testing, functional assays, genetic confirmation, and specialist centers are limited.

Research Methodology

This executive summary applies a verified, evidence-led methodology using peer-reviewed clinical guidelines, systematic reviews, regulatory drug snapshots, national treatment guidance, regional consensus statements, and real-world patient or physician surveys. The analysis excludes market sizing, share estimation, and forecasting, and instead focuses on clinical need, treatment mechanisms, regulatory milestones, access barriers, diagnostic pathways, and regional readiness. Source prioritization favored official regulators, open-access clinical journals, indexed biomedical databases, and consensus guidance; findings were cross-checked across disease epidemiology, treatment standards, and regulatory updates to maintain recency and reduce interpretation bias. Country and group insights were synthesized narratively to preserve for hereditary angioedema therapeutics, C1 inhibitor deficiency, kallikrein inhibitors, bradykinin-mediated angioedema, HAE prophylaxis, oral on-demand HAE therapy, and rare disease treatment access.

Conclusion

Hereditary angioedema therapeutics have entered a new phase defined by patient-centered control, mechanism diversity, and faster self-administered care. The strongest opportunities lie in shortening the diagnostic odyssey, improving availability of validated C4 and C1-INH testing, expanding specialist education, ensuring immediate access to on-demand therapy, and matching prophylaxis decisions to patient burden and treatment goals. Recent approvals across the United States, Europe, the United Kingdom, Australia, Canada, and Japan demonstrate accelerating innovation, while evidence from Asia-Pacific, Latin America, the Middle East, and Africa shows that therapeutic progress must be paired with practical access infrastructure. Leaders that connect science, evidence generation, digital enablement, and equitable care pathways will be best positioned to improve outcomes in this rare, unpredictable, and potentially life-threatening condition.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Prioritize Convenience as Oral and Lower-Burden Therapies Reset Patient Expectations
4.3.1.2. Expand Pediatric Pathways to Build Lifetime Treatment Value and Caregiver Loyalty
4.3.1.3. Use Modality Innovation to Broaden Treatment Choice and Attract Strategic Investment
4.3.1.4. Leverage Specialty Pharmacy and Home-Care Infrastructure to Convert Prescriptions into Persistent Use
4.3.2. Key Restraints
4.3.2.1. Prove Premium Value to Overcome Payer Controls and Rare-Disease Budget Pressure
4.3.2.2. Strengthen Supply Resilience to Protect Continuity in a High-Risk Specialty Market
4.3.3. Key Opportunities
4.3.3.1. Scale Oral Rescue Therapy as the New Standard for Patient-Initiated Attack Management
4.3.3.2. Commercialize Long-Acting Prophylaxis to Reduce Treatment Burden and Improve Persistence
4.3.3.3. Unlock Underdiagnosed Geographies Through AI-Enabled Screening and Regional Access Partnerships
4.3.4. Key Challenges
4.3.4.1. Convert Underdiagnosed Patients into Treatable Demand Through Education and Data-Driven Identification
4.3.4.2. Navigate Payer Crowding as Multiple Premium HAE Options Compete for Preferred Access
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hereditary Angioedema Therapeutics Market, by Treatment Type

7.1. Introduction
7.2. On Demand
7.2.1. Patient-Initiated Rescue
7.2.2. Clinician-Administered Rescue
7.3. Long-Term Prophylaxis
7.4. Short-Term Prophylaxis

8. Hereditary Angioedema Therapeutics Market, by Drug Class

8.1. Introduction
8.2. Bradykinin Receptor Antagonist
8.3. Plasma Kallikrein Inhibitors
8.4. Androgens
8.5. C1-Esterase Inhibitors
8.5.1. Plasma-Derived C1-INH
8.5.2. Recombinant C1-INH

9. Hereditary Angioedema Therapeutics Market, by Route Of Administration

9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous

10. Hereditary Angioedema Therapeutics Market, by Molecule Modality

10.1. Introduction
10.2. Recombinant & Plasma-Derived Proteins
10.3. Small Molecules
10.4. Monoclonal Antibodies (Biologics)
10.5. RNA-Targeted Therapeutic

11. Hereditary Angioedema Therapeutics Market, by Patient Type

11.1. Introduction
11.2. Adult
11.3. Pediatric

12. Hereditary Angioedema Therapeutics Market, by End User

12.1. Introduction
12.2. Specialty Clinics
12.3. Home Care Settings
12.4. Hospital

13. Hereditary Angioedema Therapeutics Market, by Distribution Channel

13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies

14. Hereditary Angioedema Therapeutics Market, by Region

14.1. North America
14.2. Europe
14.3. Asia-Pacific
14.4. Latin America
14.5. Middle East
14.6. Africa

15. Hereditary Angioedema Therapeutics Market, by Group

15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. GCC
15.6. ASEAN

16. Hereditary Angioedema Therapeutics Market, by Country

16.1. United States
16.2. China
16.3. Germany
16.4. Canada
16.5. Japan
16.6. United Kingdom
16.7. Brazil
16.8. Mexico
16.9. France
16.10. India
16.11. Australia
16.12. Italy
16.13. Russia
16.14. South Korea
16.15. Spain

17. Competitive Landscape

17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025

18. Company Profiles

18.1. Takeda Pharmaceutical Company Limited
18.2. CSL Limited
18.3. BioCryst Pharmaceuticals, Inc.
18.4. Pharming Group N.V.
18.5. KalVista Pharmaceuticals, Inc.
18.6. Sandoz Group AG
18.7. Neopharmed Gentili S.p.A.
18.8. Cycle Pharmaceuticals Limited
18.9. Teva Pharmaceutical Industries Ltd.
18.10. lonis Pharmaceuticals, Inc.
18.11. Sun Pharmaceutical Industries Limited
18.12. Fresenius Kabi AG
18.13. Alembic Pharmaceuticals Limited
18.14. Eugia Pharma Specialities Limited by Aurobindo Pharma Limited
18.15. Apotex Inc.
18.16. Cipla Limited
18.17. Glenmark Pharmaceuticals Limited
18.18. Adverum Biotechnologies, Inc.
18.19. Lupin Limited
18.20. ADARx Pharmaceuticals
18.21. AmbioPharm by Corden Pharma International GmbH
18.22. Argo Biopharmaceutical Co., Ltd.
18.23. Attune Pharmaceuticals, Inc.
18.24. Bachem Holding AG
18.25. BioMarin Pharmaceutical Inc.
18.26. GENESIS Pharma S.A.
18.27. Intellia Therapeutics, Inc.
18.28. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
18.29. Kaken Pharmaceutical Co., Ltd.
18.30. Octapharma AG
18.31. Orchard Therapeutics plc
18.32. Otsuka Pharmaceutical Co., Ltd.
18.33. Pharvaris N.V.
18.34. Pint Pharma
18.35. Sanofi S.A.
18.36. Spark Therapeutics Inc. by F. Hoffmann-La Roche Ltd.
18.37. Swixx Biopharma AG

List of Figures

FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ON DEMAND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ON DEMAND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ON DEMAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PATIENT-INITIATED RESCUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PATIENT-INITIATED RESCUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PATIENT-INITIATED RESCUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CLINICIAN-ADMINISTERED RESCUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CLINICIAN-ADMINISTERED RESCUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CLINICIAN-ADMINISTERED RESCUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BRADYKININ RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BRADYKININ RECEPTOR ANTAGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BRADYKININ RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANDROGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANDROGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANDROGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL C1-ESTERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL C1-ESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL C1-ESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PLASMA-DERIVED C1-INH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PLASMA-DERIVED C1-INH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PLASMA-DERIVED C1-INH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL RECOMBINANT C1-INH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RECOMBINANT C1-INH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RECOMBINANT C1-INH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL RECOMBINANT & PLASMA-DERIVED PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL RECOMBINANT & PLASMA-DERIVED PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL RECOMBINANT & PLASMA-DERIVED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MONOCLONAL ANTIBODIES (BIOLOGICS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MONOCLONAL ANTIBODIES (BIOLOGICS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MONOCLONAL ANTIBODIES (BIOLOGICS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RNA-TARGETED THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RNA-TARGETED THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RNA-TARGETED THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 102. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 103. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 141. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 142. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 143. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 144. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 146. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 147. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 152. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 153. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 155. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 157. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 158. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 162. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 163. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 165. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 167. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 168. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 181. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 182. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 183. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 184. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 185. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 187. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 191. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 192. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 193. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 195. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 197. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 198. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 201. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 202. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 203. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 204. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 207. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 208. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 222. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 223. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 224. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 225. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 226. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 228. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 229. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 233. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 234. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 238. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 239. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 241. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 243. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 244. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 245. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 246. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 248. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 249. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 253. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 254. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 256. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 257. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 258. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 259. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 267. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 268. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 271. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 272. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 273. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 274. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 275. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 276. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 277. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 278. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 279. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 280. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 281. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 283. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 284. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 285. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 286. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 288. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 289. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 292. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 293. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 294. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 295. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 296. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 297. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 298. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 299. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 300. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 301. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 302. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 303. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 304. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 305. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 306. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 307. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
TABLE 308. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 309. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 310. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 311. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 312. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 313. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
TABLE 314. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 315. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 316. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 317. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE

Companies Mentioned

Takeda Pharmaceutical Company Limited
CSL Limited
BioCryst Pharmaceuticals, Inc.
Pharming Group N.V.
KalVista Pharmaceuticals, Inc.
Sandoz Group AG
Neopharmed Gentili S.p.A.
Cycle Pharmaceuticals Limited
Teva Pharmaceutical Industries Ltd.
lonis Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Limited
Fresenius Kabi AG
Alembic Pharmaceuticals Limited
Eugia Pharma Specialities Limited by Aurobindo Pharma Limited
Apotex Inc.
Cipla Limited
Glenmark Pharmaceuticals Limited
Adverum Biotechnologies, Inc.
Lupin Limited
ADARx Pharmaceuticals
AmbioPharm by Corden Pharma International GmbH
Argo Biopharmaceutical Co., Ltd.
Attune Pharmaceuticals, Inc.
Bachem Holding AG
BioMarin Pharmaceutical Inc.
GENESIS Pharma S.A.
Intellia Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Octapharma AG
Orchard Therapeutics plc
Otsuka Pharmaceutical Co., Ltd.
Pharvaris N.V.
Pint Pharma
Sanofi S.A.
Spark Therapeutics Inc. by F. Hoffmann-La Roche Ltd.
Swixx Biopharma AG

Table Information

Report Attribute	Details
No. of Pages	180
Published	July 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 5.28 Billion
Forecasted Market Value ( USD ) by 2032	$ 7.31 Billion
Compound Annual Growth Rate	5.5%
Regions Covered	Global
No. of Companies Mentioned	37

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3208EUR$3,545USD£2,725GBP €3564EUR$3,939USD£3,028GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4853EUR$5,363USD£4,123GBP €5392EUR$5,959USD£4,581GBP

Transformative Shifts in the Hereditary Angioedema Treatment Landscape

Cumulative Impact of Artificial Intelligence on HAE Therapeutics

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7 & NATO

Key Country Insights Across Major HAE Therapeutics Markets

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Growth Forecasts, 2026-2033

Hereditary Angioedema Therapeutics Market Report 2026

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hereditary Angioedema Therapeutics: Market Share, and Growth Analysis by Product Type (C1 Inhibitors, Plasma-Derived C1 Inhibitors, Recombinant C1 Inhibitors), Application, End User, Technology